Clinical Validation of IsoPSA, a Single Parameter, Structure-Based Assay for Improved Detection of High-Grade Prostate Cancer.

Current PSA markers for prostate cancer detection are limited by low specificity for high-grade disease. IsoPSA is a blood-based, structure-focused assay that predicts risk by partitioning isoforms of PSA that are linked to cancer in an aqueous two-phase reagent system. We validated the clinical performance of IsoPSA in identifying the presence of high-grade disease in a new contemporary biopsy cohort.

Multicenter prospective validation of 271 men scheduled for prostate biopsy at seven academic and community centers enrolled between May-2017 and March-2018. Blood samples were obtained for IsoPSA prior to biopsy. Discrimination power of IsoPSA for the detection of high-grade prostate cancer (Gleason>7) was evaluated using ROC analysis and compared to prior results. Clinical performance was further improved upon comparison against multiparametric magnetic resonance imaging-ultrasound (mpMRI-US) vs. transrectal-ultrasound (TRUS) guided biopsies.

The AUC for IsoPSA was 0.784 for high-grade vs. low-grade cancer/benign histology - superior to both total PSA and % free PSA. For 1000 patients being biopsied, use of IsoPSA would have reduced unnecessary biopsies by 43% (from 705 to 402), with only 22 missed high-grade cancers, of which only 7 would have been Gleason sum 4+3 or higher. Subset analysis of mpMRI-guided biopsy produced a substantial improvement of the AUC to 0.831.

Validation of the structure-based IsoPSA assay demonstrated statistical concordance with previously reported results and verified its superior performance vs. concentration-based PSA and %fPSA. IsoPSA improvement in detecting high-grade PCa using mpMRI-US guided biopsy may help to define a new diagnostic paradigm.

The Journal of urology. 2019 Feb 15 [Epub ahead of print]

Mark Stovsky, Eric A Klein, Arnon Chait, Kannan Manickam, Andrew J Stephenson, Mathew Wagner, Martin Dineen, Yair Lotan, Alan Partin, Jack Baniel, Aimee Kestranek, Prasad Gawande, Boris Zaslavsky

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic , Cleveland , Ohio ., Cleveland Diagnostics, Inc. , Cleveland , Ohio ., Chesapeake Urology Associates , Baltimore , MD ., Kaiser Permanente Northwest , Clackamas , OR ., Advanced Urology Institute , Daytona Beach , FL., The University of Texas Southwestern Medical Center , Dallas , TX ., The Brody Urological Institute at The Johns Hopkins University , Baltimore , MD ., Rabin Medical Center , Petah-Tikva , Israel.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.